Preclinical studies of toxicity and safety of the AS-48 bacteriocin
The in vitro antimicrobial potency of the bacteriocin AS-48 is well documented, but its clinical application requires investigation, as its toxicity could be different in in vitro (haemolytic and antibacterial activity in blood and cytotoxicity towards normal human cell lines) and in vivo (e.g. mice...
Main Authors: | Rubén Cebrián, M. Elena Rodríguez-Cabezas, Rubén Martín-Escolano, Susana Rubiño, María Garrido-Barros, Manuel Montalbán-López, María José Rosales, Manuel Sánchez-Moreno, Eva Valdivia, Manuel Martínez-Bueno, Clotilde Marín, Julio Gálvez, Mercedes Maqueda |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-11-01
|
Series: | Journal of Advanced Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S209012321930133X |
Similar Items
-
Insights into Chagas treatment based on the potential of bacteriocin AS-48
by: Rubén Martín-Escolano, et al.
Published: (2019-08-01) -
Synergy of the Bacteriocin AS-48 and Antibiotics against Uropathogenic Enterococci
by: Manuel Montalbán-López, et al.
Published: (2020-09-01) -
LAB Bacteriocins Controlling the Food Isolated (Drug-Resistant) Staphylococci
by: Jesús Perales-Adán, et al.
Published: (2018-06-01) -
Analysis of the promoters involved in enterocin AS-48 expression.
by: Rubén Cebrián, et al.
Published: (2014-01-01) -
Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48
by: Marta Martínez-García, et al.
Published: (2018-08-01)